Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
APDN 
Applied DNA Sciences Inc (APDN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/17/2025: APDN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $1.5
1 Year Target Price $1.5
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -83.21% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 7.26M USD | Price to earnings Ratio - | 1Y Target Price 1.5 |
Price to earnings Ratio - | 1Y Target Price 1.5 | ||
Volume (30-day avg) 1 | Beta 0.13 | 52 Weeks Range 2.13 - 319.95 | Updated Date 10/17/2025 |
52 Weeks Range 2.13 - 319.95 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -57.12 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1213.58% |
Management Effectiveness
Return on Assets (TTM) -64.06% | Return on Equity (TTM) -137.05% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 901732 | Price to Sales(TTM) 1.94 |
Enterprise Value 901732 | Price to Sales(TTM) 1.94 | ||
Enterprise Value to Revenue 0.24 | Enterprise Value to EBITDA -0.34 | Shares Outstanding 1291465 | Shares Floating 1291439 |
Shares Outstanding 1291465 | Shares Floating 1291439 | ||
Percent Insiders 1.11 | Percent Institutions 6.92 |
Upturn AI SWOT
Applied DNA Sciences Inc
Company Overview
History and Background
Applied DNA Sciences Inc. was founded in 1983. Initially focused on DNA-based security solutions, it has evolved into a company offering DNA-based technologies for supply chain security, anti-counterfeiting, and molecular diagnostics. Significant milestones include developing SigNature DNA and expanding into biotherapeutics.
Core Business Areas
- DNA-Based Security Solutions: Provides DNA tagging and tracking solutions for supply chain security, anti-counterfeiting, and brand protection. These solutions help ensure product authenticity and traceability.
- Molecular Diagnostics: Develops and commercializes DNA-based diagnostic tests for human and animal health, focusing on rapid and accurate detection of pathogens and diseases.
- Aptamer Production: Develops and produces aptamers for various applications, including diagnostics, therapeutics, and research. Aptamers are single-stranded DNA or RNA molecules that bind to specific target molecules.
Leadership and Structure
Dr. James Hayward is the President and CEO. The company has a board of directors overseeing its strategic direction. Organizational structure is based on the key business areas.
Top Products and Market Share
Key Offerings
- SigNature DNA: DNA-based security solution for marking and authenticating products. Used in textiles, pharmaceuticals, and other industries. Market share is difficult to quantify precisely, but APDN is a recognized leader in DNA tagging. Competitors include authentication technology companies and label providers like OpSec Security and Avery Dennison.
- LineaTM DNA: Linear, double-stranded DNA used as a master template for nucleic acid therapeutics and diagnostics. No reliable market share data. Competitors include companies producing plasmid DNA such as Aldevron (Danaher), Thermo Fisher Scientific.
Market Dynamics
Industry Overview
The industries in which Applied DNA Sciences operates are highly competitive and rapidly evolving. Supply chain security is driven by globalization and the need to combat counterfeiting. Molecular diagnostics is growing due to advancements in technology and increasing demand for personalized medicine. The aptamer market is emerging with potential applications in therapeutics and diagnostics.
Positioning
Applied DNA Sciences Inc. is positioned as a leader in DNA-based security solutions and an innovator in molecular diagnostics and biotherapeutics. Its competitive advantages include its patented DNA tagging technology and its expertise in DNA manufacturing.
Total Addressable Market (TAM)
The estimated TAM for DNA-based security solutions, molecular diagnostics, and biotherapeutics is in the billions of dollars. APDN is focused on capturing market share in these segments with its proprietary technologies.
Upturn SWOT Analysis
Strengths
- Proprietary DNA tagging technology
- Expertise in DNA manufacturing
- Established partnerships with key industry players
- IP portfolio
Weaknesses
- Limited financial resources
- Dependence on key customers
- Relatively small market capitalization
- History of fluctuating revenue
Opportunities
- Expanding applications of DNA tagging in new industries
- Growing demand for molecular diagnostics
- Strategic partnerships and acquisitions
- Government contracts related to biosecurity.
Threats
- Competition from established players
- Technological advancements by competitors
- Regulatory changes
- Economic downturns
Competitors and Market Share
Key Competitors
- SNPS
- ILMN
- TMO
Competitive Landscape
Applied DNA Sciences Inc. faces intense competition from larger, more established companies with greater financial resources. Its advantages lie in its proprietary DNA tagging technology and expertise in certain niche markets.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been inconsistent, with periods of rapid expansion followed by contractions.
Future Projections: Analyst estimates for future growth vary widely, reflecting the uncertainty surrounding the company's prospects. Success in molecular diagnostics and biotherapeutics is crucial for future growth.
Recent Initiatives: Recent initiatives include expanding its diagnostic testing capabilities and partnerships for LINEA DNA.
Summary
Applied DNA Sciences Inc. is a small company with a unique DNA tagging technology, but it faces significant financial challenges and intense competition. Its success depends on expanding its diagnostic testing capabilities and achieving profitability. Investors should be aware of the high risk associated with this stock. The company has some novel technologies, but needs to be careful in spending.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Website
- Third-party financial data providers
- Analyst Reports
- Press Releases
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual risk tolerance and due diligence. Market data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Applied DNA Sciences Inc
Exchange NASDAQ | Headquaters Stony Brook, NY, United States | ||
IPO Launch date 2003-07-15 | President, CEO Chief Legal Off, Executive Director of Business Dev & President of LineaRx, Inc. Mr. Clay Shorrock Esq., J.D. | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 46 | Website https://www.adnas.com |
Full time employees 46 | Website https://www.adnas.com | ||
Applied DNA Sciences, Inc., a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment develops and commercializes the LinearDNA platform, which enables a cell-free manufacture of high-fidelity synthetic DNA sequences for use in nucleic acid-based therapeutics. The MDx Testing Services segment provides clinical molecular diagnostics (MDx) testing and clinical laboratory testing services; COVID-19 testing services, including test scheduling, sample collection, and automated results reporting for higher education institutions, private clients, and businesses under the safeCircle trademark; polymerase chain reaction (PCR) for production and detection of DNA and RNA; and MDx test kits and related supplies, as well as Isotopic analysis testing services. The DNA Tagging and Security Products and Services segment offers SigNature Molecular Tags, which provides a methodology to authenticate goods within large and complex supply chains for materials, such as cotton, nutraceuticals, and other products; SigNify portable DNA readers and SigNify consumable reagent test kits; and fiberTyping, which uses PCR-based DNA detection to detect a product's naturally occurring DNA sequences for the purposes of product provenance authentication and supply chain security. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. The company was founded in 1983 and is headquartered in Stony Brook, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.